Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantifying the Effect of Fat and Protein on the Postprandial Glucose Excursion in Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System.

Journal of diabetes science and technology·2026
Same author

Integrated glucagon model for estimation of α-cell responsivity to glucose and amino acids during graded glucose infusion.

American journal of physiology. Endocrinology and metabolism·2026
Same author

Novel deuterium metabolic imaging technique reveals distinct patterns of postprandial hepatic glucose homeostasis in individuals with type 1 diabetes and healthy control individuals: a case-control study.

Diabetologia·2026
Same author

Hepatic steatosis in humans is associated with preserved glucagon action on amino acid metabolism.

The Journal of clinical investigation·2025
Same author

Nonlinear Mixed Effects Modeling of Glucagon Kinetics Assessed Using [<sup>13</sup>C<sup>15</sup>N]-Glucagon in Individuals With and Without Type 1 Diabetes.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025
Same author

Postprandial Glucagon Metabolism in Healthy and Type 1 Diabetes.

Diabetes·2025
Same journal

Females Are Completely Resistant to Semaglutide-Induced Muscle Loss in ob/ob Mice.

Diabetes·2026
Same journal

Ketone Bodies Derived From Medium-Chain Triglycerides Support Brain Metabolism and Function Under Hypoglycemia in Type 1 Diabetes Mellitus.

Diabetes·2026
Same journal

Targeting the ADA/ADO Axis Rescues β-Cell Failure in Type 2 Diabetes.

Diabetes·2026
Same journal

TXNIP Is Positioned as a Key Mediator of Hyperglycemia-Induced Vascular Senescence.

Diabetes·2026
Same journal

Sex Differences in ER Stress Pathways Are a Key Determinant of β-Cell Proliferation and Resilience.

Diabetes·2026
Same journal

The Mechanism of TNF-α Combined With High Glucose in Regulating Calnexin Aggravates Endoplasmic Reticulum Stress in Endothelial Cell Injury of Diabetic Retinopathy.

Diabetes·2026
See all related articles

Related Experiment Video

Updated: Jul 4, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic

Balasubramanian Ravikumar1, Jean Gerrard, Chiara Dalla Man

  • 1Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, U.K.

Diabetes
|June 7, 2008
PubMed
Summary
This summary is machine-generated.

Pioglitazone significantly reduced liver fat and improved endogenous glucose production (EGP) in type 2 diabetes patients. This suggests that lowering hepatic triglyceride content is key to enhancing glucose metabolism.

Related Experiment Videos

Last Updated: Jul 4, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Area of Science:

  • Metabolic diseases
  • Endocrinology
  • Pharmacology

Background:

  • Hepatic triglyceride accumulation is linked to insulin resistance and impaired glucose metabolism in type 2 diabetes.
  • Thiazolidinediones are known to reduce hepatic triglyceride content.

Purpose of the Study:

  • To investigate the impact of pioglitazone on hepatic triglyceride levels.
  • To determine the effect of pioglitazone-induced changes in hepatic triglyceride on postprandial endogenous glucose production (EGP) in type 2 diabetes.

Main Methods:

  • Ten type 2 diabetes patients received 30 mg of pioglitazone daily for 16 weeks.
  • Endogenous glucose production (EGP) was measured using isotopic methods after a liquid meal.
  • Liver and muscle triglyceride content were quantified using 1H magnetic resonance spectroscopy.

Main Results:

  • Pioglitazone treatment led to a 50% reduction in hepatic triglyceride content (P = 0.03).
  • Fasting and postprandial EGP were significantly reduced following pioglitazone therapy (P = 0.005 and P < 0.001, respectively).
  • Reduced hepatic triglyceride content directly correlated with improved fasting EGP and EGP suppression.

Conclusions:

  • Pioglitazone effectively decreases hepatic triglyceride levels in type 2 diabetes.
  • The reduction in hepatic triglyceride content is closely associated with improvements in both fasting and postprandial EGP.